Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Indianapolis, Indiana 46202


Purpose:

The study is designed to assess the safety, tolerability, maximum tolerated dose, and clinical benefit of treatment with ENMD-2076 administered orally once daily over a range of doses in patients with relapsed or refractory multiple myeloma.


Criteria:

Major Inclusion Criteria: 1. Histological evidence of MM and evidence of relapse or refractory disease. Patients with non secretory myeloma or plasmacytoma only will be excluded. 2. Patients must have failed thalidomide, lenalidomide, or velcade or be intolerant or ineligible to receive these agents. 3. Age ≥18 years. 4. ECOG performance status 0-2. 5. Patients must have adequate organ and marrow function Major Exclusion Criteria: 1. Prior cytotoxic chemotherapy or investigational agent within 28 days or autologous stem cell transplant within 6 months of receiving study drug ENMD-2076. 2. Prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis). 3. Concomitant corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions. 4. Have unstable angina pectoris or recent myocardial infarction (within 6 months. 5. Have uncontrolled hypertension or congestive heart failure.


NCT ID:

NCT00806065


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Indianapolis, Indiana 46202
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.